Early RUBY-3 Data Shows Promise for Povetacicept in Glomerulonephritis
Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.
Source: hcplive.com
Page 16 - Immune Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Immune Sciences Today - Breaking & Trending Today
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new...
Source: marketscreener.com
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday - Arcellx (NASDAQ:ACLX), ADT (NYSE:ADT)
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.
Source: benzinga.com
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Arcellx (NASDAQ:ACLX), Acurx Pharmaceuticals (NASDAQ:ACXP)
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Source: benzinga.com
Brokerages Set Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Price Target at $18.14
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the […]
Source: defenseworld.net